Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

BerGenBio doses first patient in Phase I ADCT-601 trial

BerGenBio has developed ADCT-601 as an AXL-targeting antibody drug conjugate. Credit: rawpixel on Unsplash.



  • BerGenBio

Go Top